

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**1 - 23. (Cancelled)**

**24. (Previously presented)** A method for treating a neurodegenerative disorder or disease in which there is accumulation of misfolded and/or aggregated proteins, selected from the group consisting of Huntington's disease and Alzheimer's disease, said method comprising administering to an individual in need thereof an active agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

**25. (Cancelled)**

**26. (Previously presented)** The method in accordance with claim 24, wherein said active agent is Copolymer 1.

**27. (Cancelled)**

**28. (Withdrawn)** The method in accordance with claim 24, wherein said active agent is T cells which have been activated by Copolymer 1.

**29-30. (Cancelled)**

**31. (Withdrawn)** A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection from glutamate toxicity in a patient suffering from Alzheimer's disease, which comprises administering to an individual in need thereof an effective amount of an active agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

**32. (Previously presented)** A method for reducing disease progression, and/or for protection from neurodegeneration and/or protection from glutamate toxicity in a patient suffering from Huntington's disease, which comprises administering to said patient in need thereof an effective amount of an active agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii)

a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

**33. (Cancelled)**

**34. (Previously presented)** A method for treatment of a patient suffering from a neurodegenerative disease or disorder selected from the group consisting of Huntington's disease and Alzheimer's disease, which comprises immunizing said patient with a vaccine comprising an amount of Copolymer 1 effective for reducing disease progression in said patient.

**35. (Previously presented)** A method for treatment of a patient suffering from neurodegenerative disease or disorder selected from the group consisting of Huntington's disease and Alzheimer's disease, which comprises immunizing said patient with a vaccine comprising an amount of Copolymer 1 effective for protection from neurodegeneration in said patient.

**36. (Currently Amended)** A method for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with Huntington's disease or Alzheimer's disease, said method comprising administering to an individual in need an active agent selected from the group

| consisting of (i) Copolymer 1, (ii) a Copolymer 1-related  
peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T  
cells activated with(i), (ii) or (iii).

**37. (Previously presented)** The method according to  
claim 36, wherein said active agent is Copolymer 1.